drugset
drugset / Trial / NCT06517953

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

NCT06517953 ↗

Phase 2 Recruiting 23 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

This research study aims to explore the combination of two targeted drugs as first-line treatment for Non-Small Cell Lung Cancer (NSCLC) with uncommon EGFR mutation.

Timeline

Start
2024-07-17
Primary completion
2026-07-30
Completion
2027-12-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Befotertinib Small molecule 100 mg Oral
Subject Icotinib Small molecule 125 mg Oral

Indications

non-small cell lung carcinoma